Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study using
Adolescent
Adult
Aged
Aorta
/ diagnostic imaging
Case-Control Studies
Dermatologic Agents
/ therapeutic use
Feasibility Studies
Female
Fluorodeoxyglucose F18
Humans
Inflammation
/ complications
Liver
/ diagnostic imaging
Male
Middle Aged
Positron Emission Tomography Computed Tomography
Psoriasis
/ complications
Radiopharmaceuticals
Severity of Illness Index
Spleen
/ diagnostic imaging
Ustekinumab
/ therapeutic use
Vasculitis
/ complications
Young Adult
PET/CT
cardiovascular disease
metabolic syndrome
positron emission tomography–computed tomography
psoriasis
ustekinumab
Journal
Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
27
04
2017
revised:
04
03
2018
accepted:
11
03
2018
pubmed:
22
3
2018
medline:
30
4
2019
entrez:
22
3
2018
Statut:
ppublish
Résumé
Evidence suggests that psoriasis might be associated with metabolic syndrome and an increased risk for cardiovascular disease. To determine whether ustekinumab reduces systemic and vascular inflammation associated with metabolic syndrome and cardiovascular disease, measured using Patients with psoriasis and healthy controls underwent baseline After a Psoriasis Area and Severity Index of 75 was achieved with ustekinumab treatment, standardized uptake values were reduced in the liver, spleen, and 5 parts of the aorta (P < .05). Our study does not provide outcome data concerning cardiovascular events or metabolic syndrome; it only shows surrogate markers in a limited (Korean) population. Ustekinumab treatment was significantly associated with decreased systemic and vascular inflammation related to metabolic syndrome and cardiovascular disease among patients with psoriasis.
Sections du résumé
BACKGROUND
BACKGROUND
Evidence suggests that psoriasis might be associated with metabolic syndrome and an increased risk for cardiovascular disease.
OBJECTIVE
OBJECTIVE
To determine whether ustekinumab reduces systemic and vascular inflammation associated with metabolic syndrome and cardiovascular disease, measured using
METHODS
METHODS
Patients with psoriasis and healthy controls underwent baseline
RESULTS
RESULTS
After a Psoriasis Area and Severity Index of 75 was achieved with ustekinumab treatment, standardized uptake values were reduced in the liver, spleen, and 5 parts of the aorta (P < .05).
LIMITATIONS
CONCLUSIONS
Our study does not provide outcome data concerning cardiovascular events or metabolic syndrome; it only shows surrogate markers in a limited (Korean) population.
CONCLUSION
CONCLUSIONS
Ustekinumab treatment was significantly associated with decreased systemic and vascular inflammation related to metabolic syndrome and cardiovascular disease among patients with psoriasis.
Identifiants
pubmed: 29559399
pii: S0190-9622(18)30461-4
doi: 10.1016/j.jaad.2018.03.011
pii:
doi:
Substances chimiques
Dermatologic Agents
0
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Ustekinumab
FU77B4U5Z0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1322-1331Informations de copyright
Copyright © 2018 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.